Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Steroidomic Changes in the Cerebrospinal Fluid of Women with Multiple Sclerosis

R. Kancheva, E. Kubala Havrdová, M. Velíková, L. Kancheva, J. Včelák, R. Ampapa, M. Židó, I. Štětkářová, T. Škodová, M. Hill

. 2025 ; 26 (12) : . [pub] 20250619

Language English Country Switzerland

Document type Journal Article

Grant support
NU20-04-00450 Czech Research Health Council

Multiple sclerosis (MS) is a long-term disease that causes inflammation and damage to the nervous system. This study evaluated steroidomic alterations related to MS in 57 female MS patients during the follicular phase and 17 during the luteal phase, as well as in age- and phase-matched controls. The data showed that (1) unconjugated and conjugated steroids were strongly linked between the blood and CSF. (2) MS patients have lower levels of unconjugated steroids compared to controls. However, unchanged levels of conjugated steroids suggest a possible increase in steroid sulfotransferase functioning. (3) MS patients show altered levels of steroids linked to 11β-hydroxylase (CYP11B1) function. While direct enzyme activity was not measured, disrupted cortisol biosynthesis-potentially linked to reduced functioning of both CYP11B1 and 17α-hydroxylase/17,20-lyase-is associated with more severe cases of MS. (4) Reduced levels of 5α/β-steroids and protective GABAergic 3α-hydroxy-5α/β-steroids in MS patients might be linked to the pathophysiology of MS. (5) A potential increase in AKR1C3 function in MS could contribute to inflammation, as this enzyme catalyzes the synthesis of both steroids and prostaglandins. However, direct measurements of enzyme activity are needed to confirm this hypothesis. (6) Lower pregnenolone levels in MS patients might weaken neuroprotection, while higher pregnenolone sulfate levels could support cognitive function. (7) Lower levels of protective pregnenolone, DHEA, and androstenediol were associated with worse MS, suggesting these steroids may help shield against the disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015283
003      
CZ-PrNML
005      
20250731090905.0
007      
ta
008      
250708s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms26125904 $2 doi
035    __
$a (PubMed)40565362
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kancheva, Radmila $u Institute of Endocrinology, 11000 Prague, Czech Republic
245    10
$a Steroidomic Changes in the Cerebrospinal Fluid of Women with Multiple Sclerosis / $c R. Kancheva, E. Kubala Havrdová, M. Velíková, L. Kancheva, J. Včelák, R. Ampapa, M. Židó, I. Štětkářová, T. Škodová, M. Hill
520    9_
$a Multiple sclerosis (MS) is a long-term disease that causes inflammation and damage to the nervous system. This study evaluated steroidomic alterations related to MS in 57 female MS patients during the follicular phase and 17 during the luteal phase, as well as in age- and phase-matched controls. The data showed that (1) unconjugated and conjugated steroids were strongly linked between the blood and CSF. (2) MS patients have lower levels of unconjugated steroids compared to controls. However, unchanged levels of conjugated steroids suggest a possible increase in steroid sulfotransferase functioning. (3) MS patients show altered levels of steroids linked to 11β-hydroxylase (CYP11B1) function. While direct enzyme activity was not measured, disrupted cortisol biosynthesis-potentially linked to reduced functioning of both CYP11B1 and 17α-hydroxylase/17,20-lyase-is associated with more severe cases of MS. (4) Reduced levels of 5α/β-steroids and protective GABAergic 3α-hydroxy-5α/β-steroids in MS patients might be linked to the pathophysiology of MS. (5) A potential increase in AKR1C3 function in MS could contribute to inflammation, as this enzyme catalyzes the synthesis of both steroids and prostaglandins. However, direct measurements of enzyme activity are needed to confirm this hypothesis. (6) Lower pregnenolone levels in MS patients might weaken neuroprotection, while higher pregnenolone sulfate levels could support cognitive function. (7) Lower levels of protective pregnenolone, DHEA, and androstenediol were associated with worse MS, suggesting these steroids may help shield against the disease.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a roztroušená skleróza $x mozkomíšní mok $x krev $7 D009103
650    _2
$a dospělí $7 D000328
650    12
$a steroidy $x mozkomíšní mok $x krev $7 D013256
650    _2
$a lidé středního věku $7 D008875
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a folikulární fáze $x mozkomíšní mok $7 D005498
650    _2
$a mladý dospělý $7 D055815
650    _2
$a luteální fáze $x mozkomíšní mok $7 D008183
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubala Havrdová, Eva $u Department of Neurology, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic $1 https://orcid.org/0000000295434359 $7 nlk19990073204
700    1_
$a Velíková, Marta $u Institute of Endocrinology, 11000 Prague, Czech Republic
700    1_
$a Kancheva, Ludmila $u Institute of Endocrinology, 11000 Prague, Czech Republic
700    1_
$a Včelák, Josef $u Institute of Endocrinology, 11000 Prague, Czech Republic $1 https://orcid.org/0000000265460580 $7 xx0107261
700    1_
$a Ampapa, Radek $u MS Center, Jihlava Hospital, 58633 Jihlava, Czech Republic $1 https://orcid.org/0000000310623749
700    1_
$a Židó, Michal $u Department of Neurology 3FM CU and UHKV, Third Faculty of Medicine, Charles University, 12808 Prague, Czech Republic
700    1_
$a Štětkářová, Ivana $u Department of Neurology 3FM CU and UHKV, Third Faculty of Medicine, Charles University, 12808 Prague, Czech Republic $1 https://orcid.org/0000000326991124 $7 xx0030376
700    1_
$a Škodová, Tereza $u Institute of Endocrinology, 11000 Prague, Czech Republic $1 https://orcid.org/0000000319386946
700    1_
$a Hill, Martin $u Institute of Endocrinology, 11000 Prague, Czech Republic $1 https://orcid.org/0000000217050835 $7 mzk2005304431
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 26, č. 12 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40565362 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090900 $b ABA008
999    __
$a ok $b bmc $g 2366255 $s 1252408
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 12 $e 20250619 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NU20-04-00450 $p Czech Research Health Council
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...